Lyell Immunopharma, Inc. (LYEL)

Market Cap	819.02M
Revenue (ttm)	41,000
Net Income (ttm)	-325.66M
Shares Out	21.22M
EPS (ttm)	-21.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	137,434
Open	38.00
Previous Close	38.60
Day's Range	37.00 - 39.07
52-Week Range	7.65 - 45.00
Beta	-0.11
Analysts	Strong Buy
Price Target	25.00 (-35.15%)
Earnings Date	Nov 12, 2025

About LYEL

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi‑R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 17, 2021
• Employees: 300
• Stock Exchange: NASDAQ
• Ticker Symbol: LYEL
• Website: https://www.lyell.com

Financial Performance

In 2024, Lyell Immunopharma's revenue was $61,000, a decrease of -53.08% compared to the previous year's $130,000. Losses were -$342.99 million, 46.2% more than in 2023.

Analyst Summary

According to 3 analysts, the average rating for LYEL stock is "Strong Buy." The 12-month stock price target is $25.0, which is a decrease of -35.15% from the latest price.

Price Target

$25.0

(-35.15% downside)

Analyst Consensus: Strong Buy